Clinical Trial: Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07620405) titled 'Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease' on May 27.

Brief Summary: This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Study Start Date: July, 2027

Study Type: INTERVENTIONAL

Condition: Thyroid Eye Disease (TED)

Intervention: DRUG: MHB018A injection

MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd

Disclaimer: Curated by HT Syndication....